FDA approves Boston Scientific’s Lotus Edge aortic valve system
Boston Scientific has secured approval from the US Food and Drug Administration (FDA) for its Lotus Edge aortic valve system to treat patients with severe aortic stenosis.
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn MoreBoston Scientific has secured approval from the US Food and Drug Administration (FDA) for its Lotus Edge aortic valve system to treat patients with severe aortic stenosis.
Medical devices developer VisCardia has completed enrollment of patients and three month follow-up visits in its pilot study of VisONE implantable system.
Paragonix Technologies has initiated global post-market registry to asses clinical outcomes in patients receiving donor hearts transported with the firm’s SherpaPak cardiac transport system (CTS).
UK-based medical device manufacturer Medtronic has announced five-year outcomes from the VeClose Extension Study, which showed that VenaSeal Closure System durable and consistent for long-term in treating patients with chronic venous disease.
Bardy Diagnostics (BardyDx) has secured $35.5m series B funding to further expedite the growth of its P-wave focused cardiac monitoring platform.
Finding a biomarker for Alzheimer's disease patients that translates into clinical meaningfulness has been a real challenge for the biomarkers space
Medical technology company Stryker has launched its latest defibrillation solution, the LIFEPAK CR2 defibrillator with LIFELINKcentral AED program manager, in the US.
Biotronik today announced the United States (US) commercial launch of the PK Papyrus covered coronary stent system for use in the emergency treatment of acute coronary perforations.
Irish medical technology company Medtronic announced the results of an analysis on the impact of stroke severity in patients receiving its HeartWare HVAD System as destination therapy.
Medical device firm TherOx has secured premarket approval from the US Food and Drug Administration (FDA) for its SuperSaturated Oxygen (SSO2) Therapy for the treatment of heart attack.